Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Scinai Immunotherapeutics Ltd

Healthcare US SCNI

0.4123USD
-0.0267(6.08%)

Last update at 2026-06-05T20:06:00Z

Day Range

0.370.42
LowHigh

52 Week Range

1.906.97
LowHigh

Fundamentals

  • Previous Close 0.44
  • Market Cap2.91M
  • Volume1256728
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.98900M
  • Revenue TTM0.66M
  • Revenue Per Share TTM0.82
  • Gross Profit TTM -0.58000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -5.79600M -39.97800M -1.38546M -109.19400M -23.29324M
Minority interest - - - - -
Net income -5.79600M -39.97800M -1.38546M -109.19400M -23.29324M
Selling general administrative 5.30M 23.98M 16.14M 9.35M 5.09M
Selling and marketing expenses - - -10.94653M - 3.72M
Gross profit - - - - -
Reconciled depreciation 0.56M 2.42M 2.44M 1.65M -
Ebit -11.06100M -34.85900M 1.04M -78.50300M -19.94324M
Ebitda -10.49900M -32.44400M 3.48M -76.85800M -19.68324M
Depreciation and amortization 0.56M 2.42M 2.44M 1.65M 0.26M
Non operating income net other - - - - -
Operating income -11.06100M -34.82900M 2.28M -78.35100M -20.46280M
Other operating expenses 11.06M 34.83M -2.28079M 78.35M 20.46M
Interest expense - 10.83M 4.86M 14.92M 3.61M
Tax provision - - - - -
Interest income 5.26M 0.00300M 1.20M 0.00400M -
Net interest income 5.26M -10.86200M -3.66625M -15.07000M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 10.83M -8.20062M 14.92M 6.19M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 11.06M 34.83M -2.28079M 78.35M 20.46M
Cost of revenue - - - - -
Total other income expense net 5.26M 5.71M -10.62600M -15.77300M 2.84M
Discontinued operations - - - - -
Net income from continuing ops -5.79600M -39.97800M -1.38546M -109.19400M -
Net income applicable to common shares -5.79600M -8.20600M -4.45500M -109.19400M -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 13.45M 17.47M 27.07M 99.60M 17.70M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - 0.14M 0.14M -
Total liab 3.47M 22.04M 28.83M 76.27M 22.24M
Total stockholder equity 9.98M -4.56900M -1.76000M 23.33M -4.53919M
Deferred long term liab - - - - -
Other current liab - 0.85M 1.24M 3.33M 0.39M
Common stock - - - - -
Capital stock 5.63M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -117.53900M -122.33500M -115.83500M -364.77100M -101.00698M
Other liab - - 5.33M - 1.23M
Good will - - - - -
Other assets - - - - 0.47M
Cash 1.96M 4.87M 14.07M 54.04M 2.93M
Cash and equivalents - - - - -
Total current liabilities 1.81M 1.78M 2.34M 7.21M 19.96M
Current deferred revenue - - - - -
Net debt - 15.69M 7.47M 15.70M 17.96M
Short term debt - 0.40M 0.38M 0.77M 18.99M
Short long term debt - - - - 18.79M
Short long term debt total - 20.56M 21.54M 69.74M 20.89M
Other stockholder equity - 119.51M 116.08M 388.10M 96.47M
Property plant equipment - - 12.70M 14.19M 45.81M
Total current assets 2.39M 5.45M 14.37M 55.05M 3.30M
Long term investments - - - - -
Net tangible assets - - -1.76000M 0.98M -14.59600M
Short term investments - - - - -
Net receivables 0.08M 0.37M 0.11M 0.31M 0.37M
Long term debt 0.26M 19.37M 20.08M 63.25M -
Inventory - - - - -
Accounts payable 0.38M 0.54M 0.72M 3.11M 0.58M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -1.74000M -2.00700M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.44M 0.15M
Deferred long term asset charges - - - - -
Non current assets total 11.06M 12.03M 12.70M 44.55M 14.39M
Capital lease obligations 1.83M 1.19M 1.46M 6.49M 2.10M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.83600M -0.36100M -5.93500M -7.19900M -
Change to liabilities -0.17500M 0.00300M -15.19400M -3.66100M -
Total cashflows from investing activities -0.83600M -0.13900M -5.93500M -7.19900M -
Net borrowings - - -1.24000M 14.76M -
Total cash from financing activities 6.78M 67.78M 13.72M 85.21M 84.32M
Change to operating activities 0.31M 0.64M 1.18M 0.13M -
Net income -5.79600M -39.97800M -4.45500M -109.19400M -87.72700M
Change in cash -3.30200M 44.62M -63.04600M -3.41600M 4.50M
Begin period cash flow 17.52M 9.42M 72.47M 75.88M 71.38M
End period cash flow 14.21M 54.04M 9.42M 72.47M 75.88M
Total cash from operating activities -7.26500M -24.48400M -72.53900M -77.05800M -57.19300M
Issuance of capital stock 0.93M 69.00M 0.00000M 70.27M -
Depreciation 0.56M 2.42M 2.44M 1.65M 0.26M
Other cashflows from investing activities - - 0.04M 0.23M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.14M 0.06M -0.54800M 0.31M -
Sale purchase of stock - - - - -
Other cashflows from financing activities 5.84M -0.36100M 14.96M 15.53M -23.45400M
Change to netincome -2.30200M -0.39500M -55.95600M 33.72M -
Capital expenditures 0.84M 0.43M 6.13M 7.43M 23.73M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.27M 5.18M -92.73500M 11.03M 31.42M
Stock based compensation 1.60M 8.90M 9.47M 3.68M 0.26M
Other non cash items -3.90400M -1.00300M 12.74M 15.78M -1.40500M
Free cash flow -8.10100M -24.91400M -78.67100M -84.48700M -80.92400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SCNI
Scinai Immunotherapeutics Ltd		 -0.0267 6.08% 0.41 - - 4.42 0.67 13.16 1.10
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Scinai Immunotherapeutics Ltd

Jerusalem BioPark, Jerusalem, Israel

Key Executives

Name Title Year Born
Mr. Amir Reichman M.B.A., M.Sc. CEO & Director 1976
Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer 1982
Dr. Tamar Ben-Yedidia Ph.D. Chief Science Officer 1964
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA Chief Financial Officer 1970
Ms. Dalit Weinstein Fischer Chief Technology Officer NA
Mr. Joshua E. Phillipson B.Sc., M.B.A. Director of Communications & Investor Relations NA
Liat Halpert Head of Business Development & Sales NA
Ms. Moran Ahdout Fruchter L.L.B. Chief of Staff NA
Merav Kamensky Head of Quality Control NA
Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer 1983

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions